VTL vs. ELDN, CKPT, BLRX, GANX, CALC, RPHM, KRON, IMRX, SCYX, and JAGX
Should you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), BioLineRx (BLRX), Gain Therapeutics (GANX), CalciMedica (CALC), Reneo Pharmaceuticals (RPHM), Kronos Bio (KRON), Immuneering (IMRX), SCYNEXIS (SCYX), and Jaguar Health (JAGX). These companies are all part of the "medical" sector.
Vital Therapies (NASDAQ:VTL) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.
Eledon Pharmaceuticals has a consensus target price of $10.67, indicating a potential upside of 342.60%. Given Eledon Pharmaceuticals' higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Vital Therapies.
In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Vital Therapies. MarketBeat recorded 2 mentions for Eledon Pharmaceuticals and 1 mentions for Vital Therapies. Eledon Pharmaceuticals' average media sentiment score of 0.30 beat Vital Therapies' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.
15.5% of Vital Therapies shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 33.9% of Vital Therapies shares are held by company insiders. Comparatively, 19.4% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Vital Therapies has a beta of 3.51, indicating that its share price is 251% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Vital Therapies received 345 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. Likewise, 74.40% of users gave Vital Therapies an outperform vote while only 70.59% of users gave Eledon Pharmaceuticals an outperform vote.
Eledon Pharmaceuticals' return on equity of -46.15% beat Vital Therapies' return on equity.
Summary
Eledon Pharmaceuticals beats Vital Therapies on 8 of the 12 factors compared between the two stocks.
Get Vital Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vital Therapies Competitors List
Related Companies and Tools
